Introduces Next Generation Pain Management System to Address Chronic Pain
ALPHARETTA, Ga., Feb. 24, 2020 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced the U.S. Food and Drug Administration (FDA) has cleared for marketing its new, 80-Watt COOLIEF* Radiofrequency (RF) system for neurological lesion procedures. This easy-to-use system, comprised of a newly designed RF generator, peristaltic pump and therapy cables, enables physicians to perform a full spectrum of procedures including Cooled, Standard, Pulsed, TransDiscal and dual Bipolar RF.
Cooled RF is a non-opioid, minimally invasive outpatient pain management procedure that uses cooled radiofrequency energy to safely treat chronic pain by targeting the sensory nerves causing pain. Approximately 100 million U.S. adults – more than the number affected by heart disease, diabetes, and cancer combined – suffer from chronic pain conditions. Several studies have shown that the use of opioids to treat chronic pain, may actually worsen pain and functionality.
"Avanos' new Cooled RF system is intuitive and easy to use," stated Dr. Maged Guirguis, system chair of pain medicine at Ochsner Health. "The Cooled RF technology has not only helped our patients achieve significant relief from osteoarthritis pain, but it has also improved their function, thus providing a better quality of life."
This new system, which provides 60 percent more power than the legacy system, features an intuitive touchscreen interface, and independent channel control that enables physicians to start, stop and adjust on 4 probes individually, which enhances ease of use and efficiency.
"For over a decade, Avanos has been committed to driving innovation and investing in clinical evidence in RF technology," stated Joe Woody, Avanos' chief executive officer. "The addition of our new, advanced COOLIEF* RF generator demonstrates this continued commitment to introduce innovation to the marketplace as the Cooled RF authority and to provide relevant solutions that help patients effectively manage pain without the risk of addiction, so they can get back to things that matter. We're excited to debut the new system at the upcoming American Society of Interventional Pain Physicians annual meeting."
About COOLIEF: COOLIEF* Cooled RF uses water-cooled technology that enables more RF energy to safely deactivate pain-transmitting sensory nerves. This creates a larger, spherical lesion that distally projects 45% or greater beyond the probe's tip, allowing physicians to approach the target nerve from any angle. These features increase the likelihood of successful ablation and improve patient outcomes. COOLIEF* Cooled RF has been shown to provide up to 24 months of pain relief, improved physical functionality, and reduced drug utilization.
About Avanos Medical:
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior breakthrough medical device solutions to improve patients' quality of life. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit www.avanos.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/avanos-medical-inc-announces-fda-clearance-of-its-new-80-watt-coolief-radiofrequency-system-for-neurological-lesion-procedures-301010139.html
SOURCE Avanos Medical